Alpha DNA Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Burney US Factor Rotation ETF
BRNY
|
+$191K |
| 2 |
Microsoft
MSFT
|
+$49.5K |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$20.1K |
| 4 |
Netflix
NFLX
|
+$12.4K |
| 5 |
JPMorgan Chase
JPM
|
+$4.08K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$66.7K |
| 2 |
Apple
AAPL
|
+$20K |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$6.03K |
| 4 |
Union Pacific
UNP
|
+$3.33K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.62% |
| 2 | Financials | 12.11% |
| 3 | Communication Services | 8.14% |
| 4 | Industrials | 5.12% |
Similar funds
Alpha DNA Investment Management's Q2 2025 Portfolio in Review
As of Q2 2025, Alpha DNA Investment Management held 13 positions worth $8.98M, up 18% from $7.64M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Alpha DNA Investment Management deployed $516K of net new capital in Q2 2025, opening 2 new positions and adding to 5 existing holdings. Its largest new stake was Burney US Factor Rotation ETF: 4,606 shares worth $208K.
By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 32% a quarter earlier, followed by Financials and Communication Services.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $66.7K trimmed.
- Alpha DNA Investment Management's largest Q2 2025 buy was Burney US Factor Rotation ETF: 4,606 shares worth $208K.
- Alpha DNA Investment Management added most to Microsoft in Q2 2025, an estimated $49.5K increase.
- Alpha DNA Investment Management's biggest Q2 2025 reduction was Meta Platforms (Facebook), cutting an estimated $66.7K.
- Alpha DNA Investment Management's ten largest holdings make up 96% of its $8.98M portfolio in Q2 2025.
- Alpha DNA Investment Management opened 2 new positions and closed 0 in Q2 2025.
- Alpha DNA Investment Management's portfolio value rose 18% quarter-over-quarter to $8.98M.
Based on Alpha DNA Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.